Category: Press Releases

• Automobili Pininfarina begins 2024 with multiple award wins for its design
• PURA Vision awarded Silver in Conceptual Products / Automotive & Transport Product Design category at The International Design Awards
• Automobili Pininfarina named ‘Luxury Electric Performance Car Manufacturer of the Year 2024’ by LUXlife Magazine
• Battista Edizione Nino Farina crowned Best Electric Hypercar at Robb Report Monaco & Côte d’Azur Car of the Year 2024
• Full suite of assets to support the news can be found here

CAMBIANO, Italy, Feb. 06, 2024 (GLOBE NEWSWIRE) — Automobili Pininfarina has kicked off 2024 with three award wins, as it continues to build on the success of a record-breaking previous year.

LUXlife Magazine named Automobili Pininfarina ‘Luxury Electric Performance Car Manufacturer of the Year 2024’ at its annual awards.

Celebrating the unparalleled achievements and exceptional creativity in the realm of luxury, LUXlife awards honour the leaders and pioneers who redefine excellence within the industry, setting higher standards of sophistication and elegance. Automobili Pininfarina was a winner within the ‘Leaders in Luxury’ category.

This was followed by another win for the PURA Vision design concept, which was awarded Silver in Conceptual Products / Automotive & Transport Product Design at the 2024 International Design Awards.

Battista Edizione Nino Farina

PURA Vision represents the beginning of what promises to be a groundbreaking era for electric luxury vehicles and was penned by Chief Design Officer, Dave Amantea. It was unveiled at 2023 Monterey Car Week.

Dave Amantea, Chief Design Officer, commented: “Our PURA design philosophy is all about simplicity and timeless beauty, which is designed into every Automobili Pininfarina model. The elegant silhouette and dramatic proportions express this language on PURA Vision, envisioned here as a first-of-its-kind electric Luxury Utility Vehicle (e-LUV).”

The principles of the PURA philosophy, established by Automobili Pininfarina, transform the DNA of iconic models from Pininfarina SpA’s past to define the future, balancing inspiration from iconic classic cars with futuristic elements.

Inspired by classic proportions and exquisite detailing, PURA Vision presents an elegant silhouette with bold cab-rear proportions that combine timeless beauty with exquisite detailing to create a dynamic identity with unmistakable presence. Show-stopping features include its narrow glasshouse and tri-opening pillarless doors, which provide supreme access to its sophisticated cabin.

PURA Vision design concept

Most recently, the Automobili Pininfarina Battista Edizione Nino Farina was named Best Electric Hypercar at Robb Report Monaco & Côte d’Azur Car of the Year 2024. Introduced at the 2023 Goodwood Festival of Speed, it is a tribute to racing legend Nino Farina – nephew of company founder Battista ‘Pinin’ Farina and the first Formula One World Champion.

Each of the five unique examples features an exquisite detail that references a different milestone in Nino’s racing career. Finished in a bespoke Rosso Nino paint complemented by a special livery on the lower body, finished in Bianco Sestriere and Iconica Blu, the exterior design is completed by the Satin Gold 10-spoke forged aluminium Glorioso alloy wheels.

Press Contacts

Duncan Forrester Chief Communications Officer (M) +49 (0) 171 265 4094 d.forrester@automobili-pininfarina.com

Akira Shinonuma Communications Manager (M) +49 (0) 1511 0949270 a.shinonuma@automobili-pininfarina.com

FOR MORE INFORMATION, VISIT
https://automobili-pininfarina.com/media-hub

EDITOR’S NOTES

ABOUT AUTOMOBILI PININFARINA
Automobili Pininfarina is based in operational headquarters in Munich, Germany, with a team of experienced automotive executives from luxury and premium car brands. Designed, engineered and produced by hand in Italy, the Battista hyper GT and all future models will be sold in all major global markets under the brand name Pininfarina. The company aims to design experiences for the world’s foremost taste makers. Automobili Pininfarina GmbH is a 100 per cent Mahindra & Mahindra Ltd investment following the signing of a trademark licence agreement between Pininfarina S.p.A. and Mahindra & Mahindra Ltd. Pininfarina S.p.A. has an influential role in supporting design and production capacities based on its unique 94-year experience of producing many of the world’s most iconic cars.

Photos accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/666e6473-ad48-44a4-b8b4-63370c5905ba
https://www.globenewswire.com/NewsRoom/AttachmentNg/4e3f2da6-e216-479c-97fd-4f672a1d3e87
https://www.globenewswire.com/NewsRoom/AttachmentNg/5528a50f-f9b1-44f9-8a6f-86535076509

GlobeNewswire Distribution ID 1000912151

Curia recognized for its Service in the CDMO industry

ALBANY, N.Y., Feb. 05, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small Pharma group. In its 13^th year, the awards are presented by Outsourced Pharma and Life Science Leader.

“Curia is honored to receive this award,” said Philip Macnabb, CEO, Curia. “This distinction underscores our commitment to creating value for our customers across all of our R&D and manufacturing offerings, and we are especially appreciative to be acknowledged by the partners we support for that commitment.”

Winners of CDMO Leadership Awards are selected based on market research by Industry Standard Research (“ISR”) to distinguish CDMOs that meet or exceed customer expectations. For the 2024 awards, 98 contract manufacturers were evaluated by 23 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey. Respondents to the survey only evaluate companies with which they have worked on an outsourced project within the past 18 months. Curia was awarded based on the feedback of respondents in the Small Pharma category.

“Congratulations to our 2024 CDMO Leadership Award winners. By vote of your customers, you are recognized as the best in the global outsourcing development and manufacturing sector of the biopharma industry,” says Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma. “Award winners maintained and expanded capabilities and expertise to meet the needs of a diverse customer base; provided the additional quality and reliability so crucial to novel processes and products; and forged the closest relationships with customers. 2023 rang in with many unsettled questions. The 2024 CDMO Leadership Award winners are the support companies that best answered the bell over the past year.”

About Curia
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

Corporate Contact:

Viana Bhagan

Curia

+1 518 512 2111

corporatecommunications@CuriaGlobal.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/328a3a12-3a66-4a34-bdc8-e5de362efb85

GlobeNewswire Distribution ID 9031149

RIYADH, Saudi Arabia, Feb. 05, 2024 (GLOBE NEWSWIRE) — In a major scientific breakthrough, a research team from King Faisal Specialist Hospital and Research Centre (KFSH&RC), in collaboration with King Abdullah University of Science and Technology (KAUST), working alongside researchers from the UK, the US, and India, discovered a vital gene instrumental in combating malaria. This gene, termed PfAP2-MRP, is essential in the replication process of Plasmodium falciparum, the parasite that causes the most lethal strain of malaria.

Advanced laboratory techniques enabled the researchers to inhibit the PfAP2-MRP gene, revealing its critical role in the malaria parasite’s life cycle within red blood cells. This inhibition significantly disrupts the parasite’s ability to reproduce, reducing the severity of the disease’s symptoms and curbing its spread. This discovery is particularly impactful as it addresses Plasmodium falciparum malaria, which claims over half a million lives annually.

Dr. Ashraf Dada, Chairman of the Department of Pathology and Laboratory Medicine at King Faisal Specialist Hospital and Research Centre in Jeddah and the lead researcher, stated: “This discovery paves the way for the development of more effective treatments for the deadliest malaria strain, Plasmodium falciparum.” Also, this study enhances the scientific community’s understanding of the disease’s progression and its interaction with the human immune system, thereby strengthening efforts to combat this widespread malaria parasite prevalent in Africa.

Furthermore, the research demonstrated that the PfAP2-MRP gene regulates the production of genetically diverse protein receptors, allowing the parasite to evade the host’s immune system. This mechanism plays a significant role in the global spread of malaria and underscores the gene’s importance in developing future therapeutic strategies.

Published in the prestigious journal “Nature” this noteworthy study is part of a close collaboration between KFSH&RC and KAUST to engage in innovative research activities aimed at not only improving the diagnosis of microbes, bacteria, and parasites, but also underscores a global effort to combat pathogens and improve human health.

King Faisal Specialist Hospital and Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2023, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38b3fbef-fece-4a76-b326-2d57ab1b16ba

CONTACT INFORMATION 

For more information please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Awn, Media Coordination Officer, 0556294232

GlobeNewswire Distribution ID 9031968